AstraZeneca

News

AZ/Merck & Co wow ASCO with pancreatic cancer data

Finding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the only real option has been a course of chemotherapy, with unpleasant side-eff

News

AZ/Merck & Co reveal data supporting PARP drug in prostate c...

PARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest they could be used in a wide range of cancers as long as certa

News

AZ pulls back on Inovio immuno-oncology pact

AstraZeneca has decided to trim back its 2015 alliance with Inovio Pharmaceuticals, which focused on combining the biotech’s DNA cancer vaccines with AZ’s cancer immunotherapies.

Views & Analysis

Oncology round-up: AZ and Daiichi score key trial win with b...

AZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with an advanced

Events

GIC Pharma Social - Speaker Horizontal-01 (3) 29.04

Partner Content

The Pharma Social Media Conference

Pharma Social Media

News

AstraZeneca shows cardiovascular safety for roxadustat

AstraZeneca has announced that pooled analyses of the phase III trials for its kidney disease drug roxadustat confirm the drug’s cardiovascular safety – a good sign for the potential blockb

AZ/Merck & Co wow ASCO with pancreatic cancer data

AZ/Merck & Co reveal data supporting PARP drug in prostate c...

AZ pulls back on Inovio immuno-oncology pact

Oncology round-up: AZ and Daiichi score key trial win with b...

The Pharma Social Media Conference

AstraZeneca shows cardiovascular safety for roxadustat

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks